Traditional LNPs tend to aggregate and lose their encapsulation efficiency (EE) during nebulization, limiting their effectiveness for inhaled therapeutic delivery. In contrast, Cytofinity-IH LNPs maintain particle size and stability during nebulization, enabling efficient aerosol formation with EE > 90%. These aerosolized LNPs support robust delivery of RNA payloads to the lung via inhalation.
Target Tissues:
- Lungs (inhalation)
Potential Applications:
- Cystic Fibrosis (CF)
- Asthma
- mRNA Vaccines
Supporting Data:
1. Cytofinity-IH LNPs can be effectively nebulized to form aerosols.
2. Nebulized Cytofinity-IH LNPSs can deliver mRNA to the lung via inhalation.
Inhalation of nebulized Cytofinity-IH LNPs successfully generated Luc expression in the lung.